IMMUNOMODULATORS MARKET ANALYSIS

Immunomodulators Market, by Product Type (Immunosuppressants (Calcineurin Inhibitors, Glucocorticoids, Antimetabolites, and Others), Immunostimulants (Vaccines, Antibodies, and Others)), by Application (Oncology, Respiratory, HIV, and Others), by End User (Hospitals, Clinics, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Aug 2021
Code : CMI4609
Pages :179
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

Side effects associated with immunomodulating drugs
Strict regulations with respect to clinical studies by regulatory bodies

Global Immunomodulators Market: Restraint

Side effects associated with immunomodulating drugs such as Thalidomide (Thalomid), lenalidomide (Revlimid), and pomalidomide (Pomalyst) include drowsiness, exhaustion, constipation, low blood cell counts, and neuropathy (painful nerve damage). There's also a higher chance of major blood clots formation (that start in the leg and can travel to the lungs). With thalidomide, this is more common than with the other medicines (lenalidomide and pomalidomide). Additionally, strict regulations with respect to clinical studies by regulatory bodies is hampering the market growth.

Growth Drivers:

Rising prevalence of multiple sclerosis
Increasing prevalence of autoimmune disorders
Rising availability of drugs
Rising number of ongoing clinical trials for the development of immunotherapeutic agents